Medicare Part B Drug Waste From Single-Dose Vials To Be Studied By OIG
Executive Summary
HHS watchdog suggests savings to Medicare Part B could be generated if manufacturers sold smaller-size vials at lower prices; Office of Inspector General will also consider potential savings from establishing inflation-based rebates in Part B.
You may also be interested in...
Cancer Drug "Oversized" Single-Dose Vials Waste Money, Need Rethinking – Article
Amgen, Takeda and Merck push back against article’s conclusions on the waste generated by current vials for infused drugs.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.